Indikationen für die allogene Stammzelltransplantation

M. Christopeit; N. Kröger

doi:10.1055/s-0041-102957

Transfusionsmedizin, Table of Contents

Transfusionsmedizin 2015; 5(03): 151-160
DOI: 10.1055/s-0041-102957

CME-Fortbildung

Georg Thieme Verlag KG Stuttgart · New York

Indikationen für die allogene Stammzelltransplantation

M. Christopeit

,

N. Kröger

Interdisziplinäre Klinik für Stammzelltransplantation, Universitätsklinikum Hamburg-Eppendorf

› Author Affiliations

Abstract

Zusammenfassung

Die allogene hämatopoetische Stammzelltransplantation (HSZT) von verwandten oder unverwandten Spendern ist eine kurative Option für viele maligne und nicht maligne hämatologische Systemerkrankungen. Das kurative Potenzial der allogenen Stammzelltransplantation beruht neben der bei der Konditionierung eingesetzten Chemo- oder Radiotherapie im Wesentlichen auf dem über Spender-T-Zellen vermittelten Transplantat-gegen-Leukämie-Effekt. Dieses kurative Potenzial muss gegenüber den Risiken der transplantationsbedingten Morbidität und Mortalität abgewogen werden. Bei dieser Abwägung spielen neben den krankheitsspezifischen Faktoren ebenfalls die Spenderverfügbarkeit sowie das Alter und die Komorbidität des Patienten eine große Rolle. Die Indikation und Wahl des optimalen Zeitpunkts für eine allogene Stammzelltransplantation ist stetig im Wandel, bedingt durch Verbesserung im Management der transplantationsspezifischen Komplikationen, der zunehmenden Verfügbarkeit alternativer Spender und vor allem durch neue medikamentöse Behandlungsmöglichkeiten.

Key words

allogene Stammzelltransplantation - hämatologische Neoplasie - Graft-versus-Leukämie-Effekt - Graft-versus-Host-Disease - Spender-gegen-Wirt-Erkrankung

Full Text

References

Literatur
1 Sureda A, Bader P, Cesaro S et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015;
2 Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352 (9134) 1087-1092
3 Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106 (8) 2912-2919
4 Sorror M, Storer B, Sandmaier BM et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008; 112 (9) 1992-2001
5 Lee SJ, Klein J, Haagenson M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110 (13) 4576-4583
6 Passweg JR, Baldomero H, Bader P et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant 2015; 50 (4) 476-482
7 Müller CR, Mytilineos J, Ottinger H et al. Deutscher Konsensus 2013 zur immungenetischen Spenderauswahl für die allogene Stammzelltransplantation (German Consensus 2013 on Immunogenetic Donor Selection Criteria in Allogeneic Stem Cell Transplantation). Transfusionsmedizin 2014; 4 (4) 190-196
8 Bacigalupo A, Ballen K, Rizzo D et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15 (12) 1628-1633
9 Giralt S, Ballen K, Rizzo D et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15 (3) 367-369
10 Gorin NC, Labopin M, Frassoni F et al. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8; 21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26 (19) 3183-3188
11 Schlenk RF, Taskesen E, van Norden Y et al. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood 2013; 122 (9) 1576-1582
12 Cornelissen JJ, Gratwohl A, Schlenk RF et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 2012; 9 (10) 579-590
13 Christopeit M, Kuss O, Finke J et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol 2013; 31 (26) 3259-3271
14 Gratwohl A. The EBMT risk score. Bone Marrow Transplant 2011; 47 (6) 749-756
15 Kröger N, Holler E, Kobbe G et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114 (26) 5264-5270
16 Alchalby H, Zabelina T, Stubig T et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2014; 20 (2) 279-281
17 Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89 (6) 2079-2088
18 Greenberg PL, Tuechler H, Schanz J et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120 (12) 2454-2465
19 Malcovati L, Germing U, Kuendgen A et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25 (23) 3503-3510
20 Malcovati L, Hellstrom-Lindberg E, Bowen D et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013; 122 (17) 2943-2964
21 Dreger P, Corradini P, Kimby E et al. Chronic Leukemia Working Party of the EBMT. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007; 21 (1) 12-17
22 Dreger P, Schetelig J, Andersen N et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. Blood 2014; 124 (26) 3841-3849
23 Glass B, Hasenkamp J, Wulf G et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol 2014; 15 (7) 757-766
24 van Kampen RJ, Canals C, Schouten HC et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkinʼs lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29 (10) 1342-1348
25 Robinson SP, Canals C, Luang JJ et al. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant 2013; 48 (11) 1409-1414
26 Ghielmini M, Vitolo U, Kimby E et al. Panel Members of the 1st ECCoML. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 2013; 24 (3) 561-576
27 Kyriakou C, Canals C, Cornelissen JJ et al. Allogeneic stem-cell transplantation in patients with Waldenstrom macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28 (33) 4926-4934
28 Robinson S, Dreger P, Caballero D et al. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia 2015; 29 (2) 464-473
29 Dreyling M, Thieblemont C, Gallamini A et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24 (4) 857-877
30 Duarte RF, Boumendil A, Onida F et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol 2014; 32 (29) 3347-3348
31 Duarte RF, Canals C, Onida F et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28 (29) 4492-4499
32 Messer M, Steinzen A, Vervolgyi E et al. Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review. Leuk Lymphoma 2014; 55 (2) 296-306
33 Marcais A, Porcher R, Robin M et al. Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkinʼs lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2013; 98 (9) 1467-1475
34 Raiola A, Dominietto A, Varaldo R et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkinʼs lymphoma. Bone Marrow Transplant 2014; 49 (2) 190-194
35 Gahrton G, Iacobelli S, Bjorkstrand B et al. Subcommittee ECMWPPCD Autologous/reduced-intensity allogeneic stem cell transplantation vs. autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013; 121 (25) 5055-5063
36 Bruno B, Rotta M, Patriarca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356 (11) 1110-1120
37 Kröger N, Zabelina T, Klyuchnikov E et al. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplant 2013; 48 (3) 403-407
38 Schönland SO, Dreger P, de Witte T et al. Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. Bone Marrow Transplant 2012; 47 (7) 895-905
39 Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood 2012; 120 (6) 1185-1196
40 Bacigalupo A, Marsh JC. Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18–40 years without an HLA-identical sibling and failing immunosuppression. Bone Marrow Transplant 2013; 48 (2) 198-200